1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Vital Signs - Healthcare News - The Analyst's Perspect March 2014 Issue

This issue of Vital Signs, released on March 31, 2014, discusses the premium price tag of Gilead's Sovaldi, Sony's genomic partnership with Illumina, and Craig Venter’s latest venture, Human Longevity, Inc.


LIFE SCIENCES


A panel of experts convened in San Francisco, Calif., to discuss the cost-effectiveness of Sovaldi, Gilead’s breakthrough therapy for the chronic hepatitis C infection (CHC). Sovaldi has been priced at $1,000 per pill, translating to a total cost of $84,000 for a 12-week treatment course. Some patients with a tougher-to-treat viral strain will need a 24-week course, with a price tag of $168,000. The expert panel concluded that, although this new drug is an important breakthrough in the treatment of CHC, the benefit does not outweigh the cost for all patients, nor would the healthcare system be able to support coverage for all CHC patients. Thus, many managed care organizations may need to restrict this drug to only the sickest patients who have tried and failed cheaper standard therapies.


The Analyst’s Perspective by Debbie Toscano, Senior Industry Analyst, Life Sciences

Development of better antiviral drugs to fight CHC is one of the most competitive areas in the pharmaceutical industry. The need for better treatments is high due to the growing number of infected people developing liver damage as the population ages, modest cure rate of available treatments, and no preventative vaccine for this highly transmissible virus. Since most people infected with hepatitis C virus (HCV) are not aware that they are infected or even at risk of infection, the US Preventive Services Task Force has recently recommended that all people born between 1945 and 1956 receive a one-time screening, an action with the potential to increase the treatable population even more.

Table Of Contents

Vital Signs - Healthcare News - The Analyst's Perspect March 2014 Issue
Table of Contents

Premium Price Tag of First-in-Class Sovaldi May Impede Patient Access 2
Sony Enters Genome Market, Teams Up with Illumina, M3 3
Craig Venter's Latest Genomic Startup Launches with Lofty Goals 4

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

  • $ 6995
  • Industry report
  • January 2017
  • by GBI Research

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation Summary Melanoma is a type of cancer that begins in the ...

Breakthrough Therapies: Market Dynamics and Investment Opportunities

Breakthrough Therapies: Market Dynamics and Investment Opportunities

  • $ 6650
  • Industry report
  • January 2017
  • by BCC Research

Use this report to: - Analyze the challenges and opportunities of developing breakthrough therapies, compare difference fast track drug development approaches and the potential risk and rewards of gaining ...

Alpha Mannosidosis Market and Enzyme Replacement Therapy - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

Alpha Mannosidosis Market and Enzyme Replacement Therapy - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Alpha Mannosidosis Market: Overview With increase in the incidence of alpha mannosidosis worldwide the market for treatment is expected to grow in coming years. Alpha Mannosidosis is a rare inherited ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.